| 35.5799 -0.99 (-2.71%) | 08-12 13:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.01 | 1-year : | 52.57 |
| Resists | First : | 38.54 | Second : | 45.01 |
| Pivot price | 27.69  |
|||
| Supports | First : | 29.13 | Second : | 23.31 |
| MAs | MA(5) : | 31.45 |
MA(20) : | 27.02 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 2 |
Signal : | 1 |
| %K %D | K(14,3) : | 83.1  |
D(3) : | 82.7 |
| RSI | RSI(14): 77.7 |
|||
| 52-week | High : | 38.54 | Low : | 18.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALMR ] has closed above the upper band by 7.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 38.58 - 38.76 | 38.76 - 38.92 |
| Low: | 27.7 - 27.86 | 27.86 - 28 |
| Close: | 36.26 - 36.58 | 36.58 - 36.86 |
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Wed, 12 Aug 2026
Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews
Wed, 12 Aug 2026
Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure - simplywall.st
Wed, 12 Aug 2026
ALMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Tue, 11 Aug 2026
Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock²
Tue, 11 Aug 2026
Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake - Stock Titan
Tue, 11 Aug 2026
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 39.2 (%) |
| Shares Short | 2,250 (K) |
| Shares Short P.Month | 1,880 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.57 |
| Profit Margin | -49.9 % |
| Operating Margin | -47.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 98.9 % |
| Gross Profit (p.s.) | 0.71 |
| Sales Per Share | 1.25 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -55.65 |
| PEG Ratio | 0 |
| Price to Book value | -14.08 |
| Price to Sales | 28.76 |
| Price to Cash Flow | -41.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|